United Surgical Partners International, the ASC arm of Tenet Healthcare, is continuing its expansion streak, adding eight centers in the second quarter of 2025, according to a July 22 earnings call transcribed by The Motley Fool.
“USPI continues to deliver,” said Tenet CEO Saum Sutaria, MD, noting that the company expects to exceed its $250 million baseline M&A spend for the year.
CFO Sun Park echoed this focus, emphasizing that Tenet will continue to “prioritize capital investments to grow USPI through M&A.”
Tenet raised its 2025 adjusted EBITDA guidance for USPI by $70 million, now projecting between $1.99 billion and $2.05 billion. The company also upgraded its outlook for same-facility revenue growth, increasing expectations by 100 basis points to a range of 4% to 7%.
Dr. Sutaria highlighted USPI’s in-house, industry-leading revenue cycle capabilities as a key contributor to its strong performance.
“Some of the improvement in our results over the last few years has been related to real standardization, technology deployment, better reporting and advanced analytical tools that we have deployed into the ASC environment,” he said.
Looking ahead, USPI is poised to benefit from the continued shift of higher-acuity procedures to outpatient settings.
“Enabling additional innovation in the ASCs is positive for the USPI business,” Dr. Sutaria said. “It takes work and experience in higher acuity ASC procedures to actually be able to successfully move those things from an inpatient setting to an outpatient setting.”
He noted that USPI’s physician partnerships and clinical protocols are a strategic advantage in navigating that shift.
“We’re pretty advanced as an ASC operator and platform,” he said. “It gives us a platform to work with physicians to build the right protocols.”
